Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own1.80% Shs Outstand46.55M Perf Week-2.51%
Market Cap723.85M Forward P/E26.95 EPS next Y0.58 Insider Trans-23.81% Shs Float45.57M Perf Month-40.42%
Income-34.60M PEG- EPS next Q0.09 Inst Own- Short Float10.55% Perf Quarter-25.78%
Sales519.60M P/S1.39 EPS this Y-401.70% Inst Trans3.10% Short Ratio3.96 Perf Half Y-20.66%
Book/sh14.60 P/B1.07 EPS next Y-60.83% ROA-2.70% Target Price27.88 Perf Year-46.21%
Cash/sh3.40 P/C4.57 EPS next 5Y29.00% ROE-5.20% 52W Range15.60 - 33.00 Perf YTD-17.29%
Dividend- P/FCF25.67 EPS past 5Y-24.60% ROI-3.00% 52W High-52.88% Beta1.80
Dividend %- Quick Ratio1.60 Sales past 5Y12.20% Gross Margin79.20% 52W Low-0.32% ATR1.12
Employees597 Current Ratio1.80 Sales Q/Q7.40% Oper. Margin-6.90% RSI (14)24.95 Volatility4.12% 7.53%
OptionableYes Debt/Eq0.49 EPS Q/Q-132.60% Profit Margin-6.70% Rel Volume1.03 Prev Close16.50
ShortableYes LT Debt/Eq0.49 EarningsApr 27 BMO Payout- Avg Volume1.21M Price15.55
Recom2.60 SMA20-13.41% SMA50-32.73% SMA200-30.21% Volume1,249,711 Change-5.76%
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Apr-22-15Resumed Piper Jaffray Neutral
Feb-12-15Initiated MLV & Co Buy $58
Oct-30-14Reiterated MKM Partners Neutral $31.50 → $33
Aug-19-14Resumed Stifel Buy $47
May-07-14Reiterated MKM Partners Neutral $33 → $31.50
Apr-17-14Initiated Canaccord Genuity Hold $37
Apr-14-14Upgrade FBR Capital Mkt Perform → Outperform $30 → $47
Nov-01-13Upgrade MKM Partners Sell → Neutral
Nov-01-13Reiterated FBR Capital Outperform $35 → $30
Oct-30-13Initiated FBR Capital Mkt Perform $35
Oct-01-13Reiterated Aegis Capital Buy $43 → $50
Aug-01-13Reiterated Feltl & Co. Buy $40 → $43
May-02-13Downgrade MKM Partners Neutral → Sell
Apr-27-17 09:38PM  Acorda Shares Fall 5% in an Earnings Miss TheStreet.com -5.76%
05:31PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
05:06PM  Acorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses Investor's Business Daily
04:07PM  Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports TheStreet.com
03:11PM  Acorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses Investor's Business Daily
01:03PM  Edited Transcript of ACOR earnings conference call or presentation 27-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
07:42AM  Acorda Puts 4 Drugs On Back Burner After Patent Setback Investor's Business Daily
07:15AM  CORRECTING and REPLACING Acorda Provides Financial and Pipeline Update for First Quarter 2017 Business Wire
06:28AM  Acorda reports 1Q loss Associated Press
Apr-13-17 07:00AM  Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017 Business Wire
Apr-10-17 05:00AM  Bass Battled U.S. Drug Patents and Prices But Lost to Cabal Bloomberg
Apr-07-17 08:39PM  ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm PR Newswire
Apr-06-17 04:29PM  Acorda Trims 20% Of Workforce, But Looming Cuts Could Be Deeper Investor's Business Daily
10:10AM  Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline Zacks
Apr-05-17 03:09PM  Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired TheStreet.com -5.54%
06:00AM  Acorda Therapeutics to cut 20 pct of workforce Reuters
06:00AM  Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs Business Wire
Apr-03-17 05:26PM  Why Acorda Therapeutics Inc Plummeted for a Second Straight Day Motley Fool -12.38%
04:43PM  Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight Investor's Business Daily
09:05AM  Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge Zacks
08:35AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : April 3, 2017 Capital Cube
08:32AM  Acorda Therapeutics downgraded by JP Morgan
Apr-02-17 05:00PM  Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic TheStreet.com
Mar-31-17 05:14PM  Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today Motley Fool -21.50%
04:25PM  Acorda, Forward Stocks Plunge On Multiple Sclerosis Court Rulings
03:58PM  Acorda Loses Multiple Sclerosis Drug Patents at Investopedia
03:57PM  Two biotech stocks plunge after losing patent fights at CNBC
01:24PM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:45PM  Acorda Therapeutics' stock plummets toward biggest-ever loss amid disappointing patent ruling at MarketWatch
12:41PM  Acorda Therapy tanks
12:31PM  U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling Business Wire
12:15PM  Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient
12:03PM  Acorda Therapeutics Sinks on Invalidated Patents
Mar-30-17 11:30AM  Acorda Presents Data for Parkinson's Candidate CVT-301
11:30AM  Acorda Presents Data for Parkinson's Candidate CVT-301 at Investopedia
08:15AM  Blog Coverage Acorda Reported Long-term Safety Data Accesswire
Mar-29-17 06:40AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Acorda Announces Long-Term Safety Data for CVT-301 Business Wire
Mar-17-17 07:00AM  Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?
Mar-13-17 09:40AM  Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
07:00AM  Acorda Launches Alexa Skill in Conjunction with MS Awareness Month Business Wire
Mar-10-17 08:35AM  Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session -6.63%
Mar-09-17 04:32PM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +6.54%
03:43PM  Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA® Patents Business Wire
03:21PM  Acorda Stock Jumps Following Patent Challenge Win
Mar-03-17 01:04PM  ACORDA THERAPEUTICS INC Financials
Feb-27-17 05:21PM  ACORDA THERAPEUTICS INC Files SEC form 10-K, Annual Report +10.04%
07:00AM  Acorda to Present at the Cowen and Company 37th Annual Healthcare Conference Business Wire
Feb-23-17 08:38AM  Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
Feb-21-17 07:00AM  Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors Business Wire
Feb-16-17 01:20PM  Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR) at Insider Monkey
12:52PM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
Feb-15-17 04:45PM  Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC +6.50%
03:23PM  [2/15] Today's Top 10 Long/Short Estimize Signal Scores
10:55AM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
09:42AM  Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
09:27AM  Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
Feb-14-17 12:38PM  Edited Transcript of ACOR earnings conference call or presentation 14-Feb-17 1:30pm GMT
09:30AM  The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
08:30AM  Acorda Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Acorda Therapeutics Inc Earnings Release - Before Market Open
06:27AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:19AM  Acorda reports 4Q loss
06:00AM  Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 Business Wire
Feb-10-17 10:19AM  A Loud Coaching Session on the Desk
08:15AM  Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
08:15AM  Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial Accesswire
07:07AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events
Feb-09-17 02:03PM  Acorda Parkinsons drug results shot its stock up 13%. Why Wall Street is still cautious at MarketWatch +20.83%
11:07AM  Why Acorda Therapeutics Stock Is Jumping Today at Motley Fool
11:00AM  Acorda Therapeutics Stock Surges on Clinical Trial Results at TheStreet
10:38AM  Acorda Parkinsons Drug Succeeds In Phase 3 Study at Investopedia
10:25AM  Is This The Big Turnaround Acorda Needs?
09:37AM  Acorda stock surges 9% after positive late-stage clinical trial results for Parkinson's drug at MarketWatch
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
07:49AM  Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study
06:38AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 Business Wire
Feb-07-17 10:00AM  Biotechnology Executives Oppose Trump Immigration Policy at Forbes
Feb-03-17 07:00AM  Acorda Therapeutics to Present at Two Investor Conferences in February Business Wire
Feb-02-17 08:42AM  Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
06:46AM  Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
06:42AM  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Jan-31-17 07:00AM  Acorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14, 2017 Business Wire
Jan-30-17 08:31AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : January 30, 2017
Jan-25-17 09:30AM  The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Jan-24-17 12:30PM  Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market? at Insider Monkey
08:14AM  Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
Jan-23-17 05:03PM  Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
Jan-18-17 08:28AM  Kura Oncology Starts Dosing Patients in Phase II CMML Study
Jan-17-17 08:05AM  What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Jan-09-17 06:25AM  ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:00AM  Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference Business Wire
Jan-05-17 08:15AM  Post Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing Accesswire
08:12AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : January 5, 2017
Jan-03-17 02:42PM  New year, new drug prices
Dec-30-16 03:36PM  January Will Feature Some Of The Market's Most Influential Events
Dec-28-16 07:00AM  Acorda Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blight AndrewChief Scientific OfficerFeb 09Option Exercise22.1367,5861,495,678144,144Feb 13 04:13 PM
Greene Barry EDirectorFeb 09Option Exercise22.1372316,000723Feb 13 04:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Option Exercise22.1363,1831,398,24067,719Feb 13 04:15 PM
Wasman JanePresident, Intl and GCFeb 09Option Exercise22.1354,5361,206,882156,210Feb 13 04:16 PM
Wasman JanePresident, Intl and GCFeb 09Sale22.3054,5361,216,218101,674Feb 13 04:16 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Sale22.3263,1831,410,5424,536Feb 13 04:15 PM
Greene Barry EDirectorFeb 09Sale22.6572316,3760Feb 13 04:14 PM
Blight AndrewChief Scientific OfficerFeb 09Sale22.4167,5861,514,37976,558Feb 13 04:13 PM
Greene Barry EDirectorJan 03Option Exercise15.913,01748,0003,017Jan 05 04:12 PM
Greene Barry EDirectorJan 03Sale19.263,01758,1130Jan 05 04:12 PM
COHEN RONPresident and CEODec 14Option Exercise15.4940,172622,264519,860Dec 16 08:08 AM
COHEN RONPresident and CEODec 14Sale20.7540,172833,655479,688Dec 16 08:08 AM
Blight AndrewChief Scientific OfficerDec 01Sale20.764,855100,77476,558Dec 05 05:03 PM
Wasman JanePresident, Intl and GCDec 01Sale20.743,34769,400101,674Dec 05 05:15 PM
Sabella Lauren MChief Commercial OfficerDec 01Sale20.742,42950,38111,949Dec 05 05:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 01Sale20.744,41691,5944,536Dec 05 05:11 PM
Hindman Andrew A.Chief Business Dev. OfficerDec 01Sale20.724439,18049,227Dec 05 05:09 PM
COHEN RONPresident and CEODec 01Sale20.747,160148,482479,688Dec 05 05:08 PM
BLANK BURKHARDChief Medical OfficerDec 01Sale20.7410,000207,44240,000Dec 05 05:06 PM
Batycky Richard P.Chief Tech. Off. & Site HeadOct 21Sale20.302,06341,87745,916Oct 25 07:06 AM
LAWRENCE DAVIDChief, Bus. Ops & PAOOct 07Sale20.822505,2058,952Oct 11 07:31 AM
Wasman JanePresident, Intl and GCOct 03Sale20.783,75077,927105,021Oct 05 04:18 PM
Wasman JanePresident, Intl and GCSep 23Option Exercise8.505004,250109,271Sep 27 08:01 AM
Wasman JanePresident, Intl and GCSep 23Sale27.3250013,660108,771Sep 27 08:01 AM
Blight AndrewChief Scientific OfficerAug 09Option Exercise22.139,754215,85681,413Aug 11 03:54 PM
LAWRENCE DAVIDChief of Business OperationsJun 22Option Exercise8.505004,2509,702Jun 24 07:34 AM
LAWRENCE DAVIDChief of Business OperationsJun 22Sale25.0950012,5459,202Jun 24 07:34 AM
Wasman JanePresident, Intl and GCJun 10Option Exercise22.138,647191,358108,771Jun 14 08:42 AM
RAUSCHER STEVEN MDirectorJun 08Option Exercise18.651,08620,2541,086Jun 10 07:25 AM
RAUSCHER STEVEN MDirectorJun 08Sale27.831,08630,2240Jun 10 07:25 AM
Hindman Andrew A.Chief Business Dev. OfficerMay 13Sale26.114,860126,88549,670May 16 03:12 PM